1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Viyash Scientific Limited

Viyash Scientific Limited

207.75
INR
-6.50
(-3.03%)
5.38EPS
62.87P/E
121.02BMarket Cap
Nov 14Next Earn
Viyash Scientific Limited
BSE:VIYASH
(Bombay Stock Exchange)

Recent

price

207.75

P/E

ratio

62.87

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
28.44
31.43
28.73
30.46
30.8
28.85
28.35
34.75
42.08
47.67
54.76
57
57.08
54.95
68.7
77.41
81.14
Revenue per Share
-0.02
-0.13
-5.7
-8.55
-0.75
-0.89
-0.58
17.4
2
2.87
3.87
1.66
-4.88
-1.44
0.54
4.09
4.41
Basic EPS, GAAP
-0.81
-5.51
-0.34
-3.47
-3.52
-1.57
-0.3
1.87
4.78
3.06
2.51
-0.08
-2.79
-0.01
5.49
4.34
- -
Free Cash Flow per Basic Share
0.39
0.3
- -
- -
- -
- -
- -
0.2
- -
0.2
- -
0.5
- -
- -
- -
- -
- -
Dividend per Share
11.22
11.17
7.91
4.15
8.36
39.7
40.08
26.57
28.63
27.66
29.3
27.75
28.01
26.37
97.31
66.7
- -
Book Value per Share
10.25
6.81
4.09
2.34
2.68
32.11
27.12
15.61
17.42
18.24
20.5
17.73
15.65
14.45
57.1
44.55
- -
Tangible Book Value per Share
110
110
113
129
143
208
239
242
243
243
247
247
248
249
431
434
388
Basic Weighted Avg Shares
3,119
3,447
3,261
3,936
4,407
6,014
6,784
8,420
10,217
11,605
13,520
14,102
14,183
13,663
29,634
33,570
31,487
Sales/Revenue/Turnover
-52.62
9.27
-6.45
-0.42
0.55
3.87
4.73
7.2
10.09
12.56
12.96
4.78
0.02
2.71
5.98
13.42
12.85
Operating Margin (%)
188
230
286
326
329
462
661
533
419
506
506
515
557
615
2,387
2,336
1,962
Depreciation Expense
-2
-14
-647
-1,105
-107
-185
-138
4,216
487
699
954
410
-1,212
-359
232
1,773
1,712
Net Income, GAAP
215.33
- -
- -
- -
- -
- -
- -
56.91
3.41
12.79
23.55
15.43
- -
- -
- -
35.63
36.73
Effective Tax Rate (%)
-0.06
-0.41
-19.84
-28.08
-2.44
-3.07
-2.04
50.07
4.76
6.02
7.06
2.9
-8.54
-2.63
0.78
5.28
5.44
Profit Margin (%)
-352
-1,191
-1,144
-1,393
-1,229
2,002
642
1,071
1,657
2,094
2,536
2,711
2,311
1,959
7,961
13,085
- -
Working Capital
992
811
1,380
1,511
2,471
2,113
1,663
1,098
1,523
2,035
1,391
1,643
1,871
1,718
3,852
3,405
- -
LT Debt
1,238
1,280
996
613
2,528
9,479
9,940
6,846
7,469
7,318
7,763
7,401
7,492
7,130
25,649
31,147
- -
Total Equity
75.11
- -
- -
- -
- -
- -
- -
2.07
9.6
10.66
11.31
5.19
- -
- -
- -
7.73
- -
Return on Invested Capital (%)
-9.33
- -
- -
- -
- -
- -
- -
35.32
6.58
7.79
9.24
4.5
- -
- -
- -
5.01
- -
Return on Capital (%)
-0.15
-1.14
-59.48
-145.65
-11.66
-3.44
-1.44
51.91
7.19
10.03
13.49
5.77
-17.42
-5.29
1.5
6.64
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,492
- -
LT Borrowings
- -
3,021
- -
LT Finance Leases
- -
384
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
436
436
436
Market Capitalization
90,688
79,956
121,024

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
22,545
- -
Cash, Cash Equivalents & STI
- -
2,697
- -
Accounts Receivable, Net
- -
10,452
- -
Inventories
- -
8,032
- -
Total Current Liabilities
- -
9,460
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,492
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.98%
54.58%
21.43%
Free Cash Flow
-10,908.62%
-21,676.56%
-20.51%
Net Income, GAAP
-320.75%
-4.9%
663.53%
Sales/Revenue/Turnover
21.97%
26.28%
13.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3,902
3,687
7,740
7,723
29,634
2026
7,916
4,240
8,584
9,200
33,570
2027
9,464
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.26
0.11
1.79
-1.05
0.54
2026
1.27
0.59
0.89
1.2
4.09
2027
1.51
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Viyash Scientific Limited; an India-based integrated pharmaceutical and life sciences company, specializes in analytical and bioanalytical services, animal health products, and a diversified portfolio spanning active pharmaceutical ingredients, finished dosage formulations, and therapeutic supports. The company develops and validates analytical methods, conducts stability testing, and performs microbiology services for APIs and finished products across multiple dosage forms, leveraging customer-developed, in-house, and pharmacopoeia-compliant approaches. Through its subsidiaries, including Alivira Animal Health, it distributes companion animal products and extends its analytical service offerings to pharmaceutical and life sciences customers. The group maintains a multi-continental manufacturing footprint and a global client base, with operations in India and international facilities, underpinning a broad market reach across Europe, Asia, and the rest of the world. Founded in 1999 and headquartered in Mumbai, Viyash Scientific Limited operates within the pharmaceutical, nutraceutical, and life sciences segments, delivering integrated solutions that cover product development, analytical testing, quality assurance, and regulatory support for API manufacturers, contract research organizations, and end-user markets. The company emphasizes ongoing expansion through strategic partnerships, product launches, and capacity enhancements, aiming to strengthen its position in animal health, dermatology, anti-infectives, NSAIDs, and dermatological therapies while pursuing efficiencies across its integrated operations. Key recent developments include strategic alliances and potential acquisitions or mergers to consolidate its position in analytical services and animal health distribution, alongside ongoing investments in research and development, manufacturing capabilities, and regional market expansion. Viyash Scientific maintains a structured product and service catalog across categories such as analytical solutions (method validation, stability programs, microbiology testing), bioanalytical services, animal health products (therapeutics for livestock, poultry, and companion animals), active pharmaceutical ingredients, finished dosage formulations, nutraceuticals, dermatology and anti-infective therapies, and contract research services, supported by a global distribution network and regulatory-compliance-oriented operations. By focusing on quality, regulatory alignment, and end-to-end support, the company positions itself as a provider of integrated solutions for pharmaceutical, animal health, and consumer health sectors across multiple geographies.